This work elucidated the pharmacological effects and molecular mechanisms of endostar combined with cisplatin against NSCLC and further supported that METTL3 and FMOD could serve as therapeutic targets for NSCLC. The gene discussed is METTL3; the disease is non-small cell lung carcinoma.